Adjustment of Maternal Variable Rate Insulin Infusions Using Real-Time Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes
Issued Date
2023-04-01
Resource Type
ISSN
15209156
eISSN
15578593
Scopus ID
2-s2.0-85152169020
Pubmed ID
36695715
Journal Title
Diabetes Technology and Therapeutics
Volume
25
Issue
4
Start Page
293
End Page
297
Rights Holder(s)
SCOPUS
Bibliographic Citation
Diabetes Technology and Therapeutics Vol.25 No.4 (2023) , 293-297
Suggested Citation
Avari P., O'Regan A., Preechasuk L., Oliver N., Agha-Jaffar R. Adjustment of Maternal Variable Rate Insulin Infusions Using Real-Time Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes. Diabetes Technology and Therapeutics Vol.25 No.4 (2023) , 293-297. 297. doi:10.1089/dia.2022.0507 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81613
Title
Adjustment of Maternal Variable Rate Insulin Infusions Using Real-Time Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Real-time continuous glucose monitoring (CGM) in hospital holds promise; however, further evidence is required on its use to guide adjustment of variable rate intravenous insulin infusion (VRIII). We retrospectively analyzed data from 20 women with type 1 diabetes during the peripartum period who were commenced on VRIII. Data were analyzed for CGM accuracy (Dexcom G6) using point-of-care glucose-CGM matched pairs. The study was entirely observational, with no deviation from standard clinical care. Twenty women were included; median age 30 (26-35) years with first glycated hemoglobin in pregnancy of 57 (49-60) mmol/mol. Overall median absolute relative difference was 6.1 (1.6-17.3)%. The total simulated CGM-adjusted VRIII was 2.5 U per hour, compared with 2.4 U per hour with capillary blood glucose-adjusted VRIII. In this retrospective analysis of CGM adjustment of maternal VRIII, we demonstrate early feasibility and considerable accuracy. Further prospective studies are required to confirm the safety and potential efficacy of CGM-based insulin titration.